Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Genexol PM
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Breast Cancer, Lung cancer, Pancreatic caner(cytotoxic chemotheraphy)...
Contact Mikyeong Lee
Participants
You
Email me a copy of this message

Genexol-PM is a polymeric micelle formulated paclitaxel, free of Cremophor EL. Objectives with Genexol-PM are to reduce Cremophor EL-related toxicities and to increase therapeutic efficacy. Polymeric micelles are composed of hundreds of amphiphilic diblock copolymers. Block copolymers include poly-(ethylene glycol) used as nonimmunogenic carriers and biodegradable core-forming poly-(D,L-lactic acid) to solubilize hydrophobic drug. Genexol-PM showed 3-times higher maximum tolerated dose in mice vs. Taxol. Genexol-PM (vs. Taxol) showed 2-3-fold higher levels of paclitaxel in tissues including liver, spleen, kidney, lung, and tumors. In vivo antitumor efficacy of Genexol-PM was significantly higher than Taxol. Based on results from Phase I and II trials in Korea/US, the therapeutic dose recommended is 300mg/m2, much higher than Taxol (175 mg/m2). With favorable results from Phase II studies - Breast/Lung Cancer, Genexol-PM obtained a pre-market approval in Korea in July 2006. A phase IIa pancreatic cancer trial is on-going in US.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Registered in Korea, US, Japan, China, Canada, Mexico, Australia and Europe
(EP). Europe includes Great Britain, Germany, Spain, France, Italy, Holland, Belgium, Switzerland and Sweden.
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development REGISTERED / FINISHED PRODUCT
GOVERNMENT INSTITUTE